Transdermal Delivery of Sonidegib via Iontophoresis from PEDOT:PSS/Gelatin Hydrogels for Basal Cell Carcinoma Skin Cancer [PDF]
PharmaceuticsBackground/Objectives: Skin cancers belong to the most frequent cancer type with over a million cases per year. Presently, transdermal drug delivery systems (TDDS) are an attractive drug delivery route, but they still face some limitations due to the ...
Phimchanok Sakunpongpitiporn +6 more
doaj +2 more sources
Sonidegib en el tratamiento del carcinoma basocelular localmente avanzado
Actas Dermo-sifiliográficas, 2021 Resumen: Sonidegib es un inhibidor del receptor transmembrana Smoothened (SMO), de la vía de señalización de Hedgehog, indicado para el tratamiento del carcinoma basocelular localmente avanzado (CBCla), no susceptible a cirugía curativa ni a radioterapia.
O Sanmartín +2 more
exaly +3 more sources
Pathological Insights into the Limitations of Clinical and Dermoscopic Evaluations in Monitoring Sonidegib Treatment Response for Locally Advanced Basal Cell Carcinoma: A Real-World Study [PDF]
Dermatology and TherapyIntroduction Surgical excision is the standard treatment for basal cell carcinoma (BCC). For locally advanced BCC (laBCC) not suitable for surgery or radiotherapy, Hedgehog pathway inhibitors (HHIs) such as sonidegib are important options.
Xurong Liu +5 more
doaj +2 more sources
Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During Treatment [PDF]
Dermatology and TherapyIntroduction Sonidegib and vismodegib are Hedgehog pathway inhibitors (HHIs) approved for the treatment of locally advanced basal cell carcinoma (laBCC), as well as metastatic basal cell carcinoma (mBCC) for vismodegib.
Mark G. Lebwohl +10 more
doaj +2 more sources
Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database [PDF]
Scientific ReportsThis study aims to comprehensively evaluate the long-term safety profiles of hedgehog pathway inhibitors (HPIs), sonidegib and vismodegib, which have been approved for basal cell carcinoma but lack extensive real-world safety data.
Zhixing Zheng +8 more
doaj +2 more sources
Sonidegib Therapy for Locally Advanced Basal Cell Carcinoma in an Elderly Patient: A Case Report [PDF]
Clinical, Cosmetic and Investigational DermatologyYuyu Deng,1– 5 Pingxiu He,1– 5 Changxia Li,1– 5 Guolan Li,1– 5 Xiaohua Tao1– 5 1Dermatology Department, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, People’s Republic of China; 2Dermatology Department, Jiangxi Provincial Clinical Research
Deng Y, He P, Li C, Li G, Tao X
doaj +2 more sources
A Sonidegib Experience in the Treatment of Basal Cell Carcinoma with Systemic Lupus Erythematosus: A Case Report [PDF]
Clinical, Cosmetic and Investigational DermatologyLiangliang Shi,1,* Binxin Liu,1,* Pengxiang Gao,2 Xianwei Cao,1 Chuan Wan1 1Department of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China; 2Department
Shi L, Liu B, Gao P, Cao X, Wan C
doaj +2 more sources
Refractory Morpheaform Basal Cell Carcinoma Successfully Treated with Oral Sonidegib [PDF]
Clinical, Cosmetic and Investigational DermatologyYuesen Zhang,1,* Junyou Zheng,2,* Xiaofang Li,3 Yan Wang,1 Fang Fang,1 Zhiwen Wang,1 Wenbo Bu1 1Department of Dermatologic Surgery, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union
Zhang Y +6 more
doaj +2 more sources
Real-world safety profile of sonidegib: a disproportionality analysis based on the FDA adverse event reporting system [PDF]
Frontiers in OncologyBackgroundSonidegib is a novel treatment for locally advanced basal cell carcinoma (LaBCC) with demonstrated efficacy and safety in clinical trials. However, its real-world safety profile remains insufficiently characterized. This study aimed to evaluate
Kaidi Zhao +5 more
doaj +2 more sources
Real-world experience with vismodegib and sonidegib in advanced basal cell carcinoma: a multicenter Italian study [PDF]
Dermatology ReportsVismodegib and sonidegib are smoothened (SMO) inhibitors approved for the treatment of advanced basal cell carcinoma (aBCC). This study investigates the real-world experiences and outcomes associated with these therapies across multiple Italian centers ...
Mario Valenti +9 more
doaj +2 more sources